Patents by Inventor Nicolas Anfossi

Nicolas Anfossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-KIR3D antibodies
    Patent number: 9828427
    Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: November 28, 2017
    Assignee: INNATE PHARMA
    Inventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi
  • ANTI-KIR3D ANTIBODIES
    Publication number: 20160046713
    Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventors: NICOLAS ANFOSSI, LAURENT GAUTHIER, YANNIS MOREL, ALESSANDRO MORETTA, SILVIA PAROLINI, BENJAMIN ROSSI
  • Anti-KIR3D antibodies
    Patent number: 9181341
    Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: November 10, 2015
    Assignee: INNATE PHARMA
    Inventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi
  • ANTI-KIR3D ANTIBODIES
    Publication number: 20120064081
    Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
    Type: Application
    Filed: January 15, 2010
    Publication date: March 15, 2012
    Applicant: INNATE PHARMA
    Inventors: Nicolas Anfossi, Laurent Gauthier, Yannis Morel, Alessandro Moretta, Silvia Parolini, Benjamin Rossi